Midatech Pharma PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Midatech Pharma PLC
The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.
With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.
Newly installed Fortovia Therapeutics CEO Peter Melnyk tells Scrip his arrival and the company’s name change from Midatech Pharma US signals a strategic revamp for the privately held spin-out.
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
- Specialty Pharmaceuticals
- Controlled Release
- Site Specific
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- DARA BioSciences, Inc.
- MidaSol Therapeutics LP
- Midatech Group Ltd.
- Oncogenerix, Inc.
- Pharmida AG
- Point Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.